SPS
CRSP icon

Susquehanna Portfolio Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.95M Buy
164,026
+58,653
+56% +$3.09M 0.14% 194
2026
Q1 		$5.01M Buy
105,373
+74,358
+240% +$3.92M 0.07% 301
2025
Q4 		$1.63M Sell
31,015
-6,479
-17% -$388K 0.03% 545
2025
Q3 		$2.43M Buy
37,494
+6,479
+21% +$372K 0.04% 472
2025
Q2 		$1.51M Buy
31,015
+11,965
+63% +$463K 0.03% 428
2025
Q1 		$648K Buy
+19,050
New +$808K 0.28% 67
2024
Q3 		– Sell
-5,845
Closed -$316K – 388
2024
Q2 		$316K Sell
5,845
-31,433
-84% -$1.82M 0.01% 418
2024
Q1 		$2.54M Sell
37,278
-35,019
-48% -$2.51M 0.06% 299
2023
Q4 		$4.53M Buy
+72,297
New +$4M 0.08% 301

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Portfolio Strategies's CRSP Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its CRISPR Therapeutics (CRSP) stake by 56% in Q2 2026, buying an estimated $3.09M and bringing the position to 164,026 shares worth $8.95M. The position accounts for 0.14% of the portfolio, ranked #194.

Susquehanna Portfolio Strategies first reported a position in CRSP in Q4 2023 and has held it in 9 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Susquehanna Portfolio Strategies held 164,026 shares of CRISPR Therapeutics worth $8.95M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 58,653 CRISPR Therapeutics shares in Q2 2026, an estimated $3.09M.
  • CRISPR Therapeutics made up 0.14% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #194 holding.
  • Susquehanna Portfolio Strategies first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.